←Back to Expert Scholars
Translational Medicine / 转化医学ADC Payload Innovation
Feng Li
PhD
🏢RemeGen Co., Ltd.🌐China
Senior Vice President, Research
32
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Feng Li is a leading Chinese ADC researcher who has driven the development of disitamab vedotin, a HER2-targeting ADC with a novel MMAE-based design. His work has established China as a major player in ADC innovation and clinical development. He continues to advance the Chinese ADC pipeline with novel targets and payload technologies.
Share:
🧪Research Fields 研究领域
Disitamab vedotin
HER2 ADC China
Novel ADC targets
ADC manufacturing
Chinese ADC development
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Feng Li 的研究动态
Follow Feng Li's research updates
留下邮箱，当我们发布与 Feng Li（RemeGen Co., Ltd.）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment